Genetics and Heart Health After Cancer Therapy

Inclusion criteria

• ≥18 years of age
• Initial diagnosis of Breast Cancer in 2005 or later
• Documented BRCA testing (results from a local laboratory are acceptable) showing

• confirmation of a germline mutation in BRCA1 or BRCA2 that is predicted or suspected to be deleterious OR
• confirmation that no mutation was detected in BRCA1 or BRCA2
• Non-carriers will have been treated with an anthracycline-based chemotherapy regimen; carriers may or may not have been treated with an anthracycline-based chemotherapy regimen.
• Approximately at least 12 months from initiation of adjuvant treatment or neo-adjuvant chemotherapy
• Able to provide informed consent

Exclusion criteria

• Stage IV Breast Cancer
• Genetic testing confirming a variant of unknown significance (VUS) or benign polymorphism in BRCA1 or BRCA2
• V02 Testing contraindicated for any reason, including:

• Myocardial infarction (within past 3 months)
• High-risk unstable angina;
• High-risk or uncontrolled cardiac arrhythmias;
• Symptomatic severe aortic stenosis;
• Uncontrolled symptomatic heart failure;
• Acute pulmonary embolus or pulmonary infarction;
• Acute myocarditis or pericarditis;
• Acute aortic dissection;
• Coronary revascularization procedure within the past three months;
• Uncontrolled hypertension, defined as systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 100mmHg;
• Clinically significant valvular heart disease (severe stenosis or regurgitation);
• Known aortic aneurysm; or
• Any other condition which, in the opinion of the investigator, may impede testing of the study hypothesis or make it unsafe to engage in the V02 test
• Women who are pregnant
• Any other clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent